Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
XAIR 
Beyond Air Inc (XAIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: XAIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.2
1 Year Target Price $11.2
| 1 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.71% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.76M USD | Price to earnings Ratio - | 1Y Target Price 11.2 |
Price to earnings Ratio - | 1Y Target Price 11.2 | ||
Volume (30-day avg) 5 | Beta 0.25 | 52 Weeks Range 2.23 - 13.52 | Updated Date 08/15/2025 |
52 Weeks Range 2.23 - 13.52 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate -0.095 | Actual -1.53 |
Profitability
Profit Margin - | Operating Margin (TTM) -432.78% |
Management Effectiveness
Return on Assets (TTM) -64.62% | Return on Equity (TTM) -309.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18007192 | Price to Sales(TTM) 2.25 |
Enterprise Value 18007192 | Price to Sales(TTM) 2.25 | ||
Enterprise Value to Revenue 3.77 | Enterprise Value to EBITDA -4.23 | Shares Outstanding 4639740 | Shares Floating 3381417 |
Shares Outstanding 4639740 | Shares Floating 3381417 | ||
Percent Insiders 11.88 | Percent Institutions 17.98 |
Upturn AI SWOT
Beyond Air Inc
Company Overview
History and Background
Beyond Air, Inc. (formerly AIT Therapeutics, Inc.) was founded to develop a nitric oxide (NO) generator and delivery system that uses NO generated from ambient air and deliver it to treat respiratory diseases.
Core Business Areas
- LungFit PH: A medical device designed to deliver inhaled nitric oxide (iNO) for the treatment of persistent pulmonary hypertension of the newborn (PPHN). It uses a patented NO generation system that eliminates the need for high-pressure cylinders and is designed for point-of-care use in hospitals.
Leadership and Structure
Steve Lisi is the current Chairman and CEO. The company is structured with a board of directors overseeing the executive team.
Top Products and Market Share
Key Offerings
- LungFit PH: LungFit PH is the main product of Beyond Air, designed to deliver precise concentrations of NO for PPHN treatment. Although specific market share data is hard to find, competitors in the iNO space include Mallinckrodt Pharmaceuticals. Revenue is not publicly broken down by individual product yet, as it has only recently been launched.
Market Dynamics
Industry Overview
The inhaled nitric oxide (iNO) market addresses respiratory diseases and conditions, primarily in newborns and adults with pulmonary hypertension. Key drivers include technological advancements, increasing prevalence of target diseases, and growing awareness of iNO therapy.
Positioning
Beyond Air is positioned as an innovator in the iNO delivery space with its LungFit system, which offers a self-contained, portable alternative to traditional cylinder-based NO delivery systems. Its competitive advantage lies in its simplicity and ease of use.
Total Addressable Market (TAM)
The TAM for iNO therapy is estimated to be in the hundreds of millions of dollars globally. Beyond Air is positioning itself to capture a significant share of this market with its innovative technology. They are targeting the initial indication of PPHN but are also investigating other indications such as viral pneumonia.
Upturn SWOT Analysis
Strengths
- Innovative technology (LungFit)
- Portable and convenient
- Potential for expanded indications
- Elimination of reliance on NO cylinders
Weaknesses
- Limited commercial track record
- Reliance on a single product (currently)
- Need for regulatory approvals for new indications
- Relatively small company size compared to competitors
Opportunities
- Expansion into new therapeutic areas (e.g., viral pneumonia)
- International market penetration
- Partnerships with hospitals and healthcare providers
- Further development of NO delivery technology
Threats
- Competition from established players (Mallinckrodt)
- Technological obsolescence
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MNK
Competitive Landscape
Beyond Air's LungFit PH offers a unique advantage with its portability and ease of use compared to traditional cylinder-based iNO systems. However, Mallinckrodt (MNK) has a larger established market presence and a broader product portfolio.
Growth Trajectory and Initiatives
Historical Growth: Limited commercial history, so historical growth is difficult to establish yet.
Future Projections: Analyst estimates suggest revenue growth as LungFit PH gains market adoption and potential approvals for new indications. Specific growth rates are not readily available.
Recent Initiatives: Focused on commercial launch of LungFit PH, expanding manufacturing capabilities, and pursuing clinical trials for new indications.
Summary
Beyond Air is an emerging company with a potentially disruptive technology in the iNO delivery space. Its LungFit PH system offers advantages in portability and convenience, but it faces competition from larger, established players. The company's success hinges on gaining market adoption, securing regulatory approvals for new indications, and managing its cash flow effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports (where available)
- Third party market research reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beyond Air Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 2017-09-22 | CEO & Chairman of the Board Mr. Steven Adam Lisi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 61 | Website https://www.beyondair.net |
Full time employees 61 | Website https://www.beyondair.net | ||
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.